Description
A stable analogue of prostacyclin that potently and selectively activates the IP receptor (Ki = 20 nM); the active form of the prodrug NS-398 that is stable in vivo, as plasma concentrations of MRE-269 remain near peak levels for more than eight hours; exhibits lower affinity for the vasoconstricting EP3 receptor than other IP receptor agonists.
Formal name: [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid
Synonyms:
Molecular weight: 419.5
CAS: 475085-57-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Xenobiotic Metabolites||Research Area|Cardiovascular System|Vasculature|Vasodilation||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway